[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 35 of about 35
1. Xue H, Field CJ, Sawyer MB, Dieleman LA, Baracos VE: Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy. Br J Cancer; 2009 May 19;100(10):1581-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy.
  • Infectious complications are a major cause of morbidity and mortality from dose-intensive cancer chemotherapy.
  • In spite of the importance of intestinal bacteria translocation in these infections, information about the effect of high-dose chemotherapy on gut mucosal immunity is minimal.
  • We studied prophylactic ciprofloxacin (Cipro) treatment on irinotecan (CPT-11) toxicity and host immunity in rats bearing Ward colon tumour.
  • Cipro abolished chemotherapy-related mortality, which was 45% in animals that were not treated with Cipro.
  • Seven days after CPT-11, splenocytes were unable to proliferate (stimulation index=0.10+/-0.02) and produce proliferative and inflammatory cytokines (i.e., Interleukin (IL)-2, interferon-gamma (IFN-gamma), tumour necrosis factor-alpha (TNF-alpha) IL-1beta, IL-6) on mitogen stimulation in vitro (P<0.05 vs controls), whereas mesenteric lymph node (MLN) cells showed a hyper-proliferative response and a hyper-production of pro-inflammatory cytokines on mitogen stimulation.
  • This suggests compartmentalised effects by CPT-11 chemotherapy on systemic and intestinal immunity.
  • [MeSH-major] Antibiotic Prophylaxis / methods. Camptothecin / analogs & derivatives. Carcinoma / drug therapy. Ciprofloxacin / therapeutic use. Colorectal Neoplasms / drug therapy. Immunity, Mucosal / drug effects. Intestinal Mucosa / drug effects
  • [MeSH-minor] Animals. Anti-Infective Agents / pharmacology. Anti-Infective Agents / therapeutic use. Antineoplastic Agents, Phytogenic / adverse effects. Antineoplastic Agents, Phytogenic / therapeutic use. Diarrhea / chemically induced. Diarrhea / complications. Female. Lymphatic Metastasis. Neoplasm Transplantation. Rats. Rats, Inbred F344. Spleen / drug effects. Spleen / pathology. Survival Analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. CIPROFLOXACIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3270-4 [9699654.001]
  • [Cites] Drugs. 1996 Oct;52(4):606-23 [8891470.001]
  • [Cites] J Surg Res. 1998 Sep;79(1):39-46 [9735238.001]
  • [Cites] J Immunol Methods. 2004 Oct;293(1-2):127-42 [15541283.001]
  • [Cites] Ann N Y Acad Sci. 2004 Dec;1029:9-15 [15681738.001]
  • [Cites] Ann Intern Med. 2005 Jun 21;142(12 Pt 1):979-95 [15968013.001]
  • [Cites] J Nutr Biochem. 2006 Jan;17(1):37-44 [16098728.001]
  • [Cites] Infection. 2005 Dec;33 Suppl 2:55-70 [16518713.001]
  • [Cites] Clin Immunol. 2006 Apr;119(1):110-9 [16458073.001]
  • [Cites] Int Immunol. 2006 Jun;18(6):941-9 [16636014.001]
  • [Cites] Clin Immunol. 2006 Sep;120(3):239-46 [16581297.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1743-51 [16977651.001]
  • [Cites] Br J Haematol. 2000 Jan;108(1):105-15 [10651733.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2000 Sep;31(3):291-9 [10997375.001]
  • [Cites] Science. 2000 Oct 6;290(5489):97-100 [11021807.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Feb;163(2):316-21 [11179099.001]
  • [Cites] Oncologist. 2001;6(1):66-80 [11161230.001]
  • [Cites] Shock. 2001 Aug;16(2):83-96 [11508871.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3801-7 [11559717.001]
  • [Cites] Shock. 2001 Dec;16(6):454-8 [11770044.001]
  • [Cites] Vet Immunol Immunopathol. 2002 Sep 10;87(3-4):109-21 [12072225.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5778-84 [12384538.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Dec 1;166(11):1417-8 [12450929.001]
  • [Cites] N Engl J Med. 2003 Jan 9;348(2):138-50 [12519925.001]
  • [Cites] Lancet Infect Dis. 2003 Jun;3(6):359-71 [12781508.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Sep;18(9):1095-100 [12911669.001]
  • [Cites] Hematology. 2003 Oct;8(5):303-11 [14530172.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2851-9 [15102694.001]
  • [Cites] Cancer Immunol Immunother. 2004 Aug;53(8):740-7 [15133630.001]
  • [Cites] Cancer. 1976 Feb;37(2 Suppl):1058-69 [766953.001]
  • [Cites] J Clin Invest. 1986 Mar;77(3):841-9 [3005367.001]
  • [Cites] Antimicrob Agents Chemother. 1986 Feb;29(2):337-8 [2940967.001]
  • [Cites] J Antimicrob Chemother. 1986 Jun;17(6):811-4 [3090010.001]
  • [Cites] Immunol Lett. 1988 Nov;19(3):183-91 [3069706.001]
  • [Cites] Clin Immunol Immunopathol. 1990 Jan;54(1):126-33 [2403487.001]
  • [Cites] Adv Exp Med Biol. 1990;256:549-56 [2183565.001]
  • [Cites] Clin Exp Immunol. 1991 Aug;85(2):331-4 [1864014.001]
  • [Cites] Bone Marrow Transplant. 1992 Apr;9(4):285-91 [1376185.001]
  • [Cites] Eur J Immunol. 1992 Jul;22(7):1843-50 [1378021.001]
  • [Cites] Arch Surg. 1993 Jan;128(1):89-94; discussion 94-5 [8418786.001]
  • [Cites] Immunology. 1993 Jul;79(3):479-84 [8406575.001]
  • [Cites] Immunopharmacology. 1994 Mar-Apr;27(2):155-64 [8014029.001]
  • [Cites] J Surg Res. 1994 Jun;56(6):579-85 [8015314.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2221-8 [7919339.001]
  • [Cites] Chest. 1997 Jul;112(1):235-43 [9228382.001]
  • [Cites] Exp Hematol. 1997 Aug;25(9):992-1004 [9257813.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3789-98 [9345067.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 1997;45(4):277-84 [9523001.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):7146-54 [18056195.001]
  • [Cites] J Exp Med. 1994 Dec 1;180(6):2401-6 [7525854.001]
  • [Cites] J Immunol. 1995 Feb 15;154(4):1675-83 [7836751.001]
  • [Cites] Ann Surg. 1995 Oct;222(4):482-90; discussion 490-2 [7574928.001]
  • [Cites] Biotherapy. 1996;8(3-4):243-9 [8813336.001]
  • [Cites] Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):72-8 [9726096.001]
  • (PMID = 19401694.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Antineoplastic Agents, Phytogenic; 5E8K9I0O4U / Ciprofloxacin; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2696758
  •  go-up   go-down


2. Choi JH, Lim HY, Joo HJ, Kim HS, Yi JW, Kim HC, Cho YK, Kim MW, Lee KB: Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer; 2002 May 20;86(10):1578-85
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
  • Both 5-fluorouracil and doxorubicin are commonly used agents in chemotherapy of gastric cancer in adjuvant setting as well as metastatic disease.
  • We evaluated the expression of multidrug resistance-associated protein1, P-glycoprotein, and thymidylate synthase using immunohistochemistry in 103 locally advanced gastric cancer patients (stage IB-IV) who underwent 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection and investigated the association between their expression and clinicopathologic characteristics including prognosis of the patients.
  • High multidrug resistance-associated protein1 and P-glycoprotein expressions were associated with well and moderately differentiated histology (P<0.0001 and P=0.03, respectively) and intestinal type (P<0.0001 and P=0.009, respectively).
  • High multidrug resistance-associated protein1 expression correlated with lymph node metastasis (P=0.037), advanced stage (P=0.015), and older age (P=0.021).
  • In conclusion, high expression of multidrug resistance-associated protein1, P-glycoprotein, and thymidylate synthase did not predict poor prognosis of gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / chemistry. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Gastrectomy. Neoplasm Proteins / analysis. P-Glycoprotein / analysis. Stomach Neoplasms / chemistry. Thymidylate Synthase / analysis
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Immunotherapy. Lentinan / administration & dosage. Life Tables. Male. Middle Aged. Mitomycin / administration & dosage. Picibanil / administration & dosage. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] comCopyright 2002 Cancer Research UK
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1059-64 [10533448.001]
  • [Cites] Anticancer Res. 1998 May-Jun;18(3B):1903-6 [9677442.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1461(2):359-76 [10581367.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):171-7 [10638986.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6C):4809-14 [11205224.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):186-92 [11161374.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] J Clin Oncol. 1988 Oct;6(10):1653-64 [3049954.001]
  • [Cites] J Natl Cancer Inst. 1989 Jan 18;81(2):116-24 [2562856.001]
  • [Cites] Cancer. 1989 Nov 15;64(10):2053-62 [2680049.001]
  • [Cites] J Natl Cancer Inst. 1990 Nov 7;82(21):1679-83 [1977924.001]
  • [Cites] Cancer. 1991 May 15;67(10):2454-8 [2015545.001]
  • [Cites] Cancer Res. 1992 Aug 15;52(16):4306-12 [1643628.001]
  • [Cites] Science. 1992 Dec 4;258(5088):1650-4 [1360704.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1441-7 [8336183.001]
  • [Cites] Annu Rev Biochem. 1993;62:385-427 [8102521.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2640-7 [7989939.001]
  • [Cites] J Surg Oncol. 1995 Jan;58(1):63-9 [7823576.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1407-12 [7882343.001]
  • [Cites] N Engl J Med. 1995 Jul 6;333(1):32-41 [7776992.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2757-63 [7595735.001]
  • [Cites] Ann Surg Oncol. 1995 Nov;2(6):488-94 [8591078.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):231-8 [8532000.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):176-82 [8558194.001]
  • [Cites] Cancer. 1996 Apr 15;77(8 Suppl):1681-7 [8608562.001]
  • [Cites] Semin Oncol. 1996 Jun;23(3):379-89 [8658222.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):372-7 [8903480.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1923-31 [9164203.001]
  • [Cites] Oncology. 1997 Sep-Oct;54(5):391-9 [9260601.001]
  • [Cites] Br J Cancer. 1997;76(4):486-93 [9275026.001]
  • [Cites] Cancer. 1998 Oct 1;83(7):1300-6 [9762929.001]
  • [Cites] Clin Cancer Res. 1996 Jul;2(7):1231-7 [9816292.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2054-9 [9827708.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):673-80 [10100721.001]
  • [Cites] Anticancer Res. 1999 Jan-Feb;19(1B):805-10 [10216496.001]
  • [Cites] Surg Today. 1999;29(5):401-6 [10333409.001]
  • [Cites] Br J Cancer. 1998;77(1):87-91 [9459150.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):661-6 [9477097.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1533-42 [9626474.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3810-5 [10577853.001]
  • (PMID = 12085207.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 37339-90-5 / Lentinan; 39325-01-4 / Picibanil; 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2746581
  •  go-up   go-down


3. Kim MS, Cho CK, Yang KM, Lee DH, Moon SM, Shin YJ: Stereotactic body radiotherapy for isolated paraaortic lymph node recurrence from colorectal cancer. World J Gastroenterol; 2009 Dec 28;15(48):6091-5
Genetic Alliance. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic body radiotherapy for isolated paraaortic lymph node recurrence from colorectal cancer.
  • AIM: To evaluate the efficacy and complications of stereotactic body radiotherapy in localized paraaortic lymph node recurrence from colorectal cancer.
  • METHODS: From 2003 to 2009, 7 patients with paraaortic lymph node recurrence (1-3 lesions) from colorectal cancer were treated with stereotactic body radiotherapy.
  • The doses were escalated from 36 Gy/patient to 51 Gy/patient and were delivered in 3 fractions.
  • Grade IV intestinal obstruction was reported in 1 of 7 patients.
  • This patient received 48 Gy in 3 fractions with a maximum point dose to the intestine of 53 Gy and V(45Gy) = 3.6 mL.
  • However, 6 patients received an intestinal maximum point dose of < 51 Gy and V(45Gy) of < 1 mL, and did not develop any severe complications.
  • CONCLUSION: This pilot study suggests selected paraaortic lymph node recurrence (1-3 closed lesions) that failed to respond to chemotherapy can be potentially salvaged by stereotactic body radiotherapy.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Lymph Nodes / surgery. Neoplasm Recurrence, Local / radiotherapy. Radiosurgery. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):147-53 [18990511.001]
  • [Cites] Jpn J Clin Oncol. 2008 Oct;38(10):695-700 [18723850.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):442-8 [11567819.001]
  • [Cites] Dis Colon Rectum. 2002 Jun;45(6):795-801 [12072633.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1247-53 [12654434.001]
  • [Cites] Surg Gynecol Obstet. 1981 Jun;152(6):777-80 [7244953.001]
  • [Cites] Surg Gynecol Obstet. 1981 Oct;153(4):495-6 [7280937.001]
  • [Cites] Dis Colon Rectum. 1993 Jun;36(6):540-4 [7684666.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6 [7713792.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):450-5 [15667966.001]
  • [Cites] N Engl J Med. 2005 Feb 3;352(5):476-87 [15689586.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):897-909 [15785892.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4553-60 [16002847.001]
  • [Cites] Oncology (Williston Park). 2005 Aug;19(9):1147-54; discussion 1154, 1157-8, 1160 [16255132.001]
  • [Cites] Cancer Treat Rev. 2006 May;32(3):214-28 [16546323.001]
  • [Cites] J Surg Oncol. 2008 Feb 1;97(2):136-40 [17963247.001]
  • [Cites] J Korean Med Sci. 2009 Jun;24(3):488-92 [19543514.001]
  • (PMID = 20027683.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2797667
  •  go-up   go-down


Advertisement
4. Hamilton K, Chiappori A, Olson S, Sawyers J, Johnson D, Washington K: Prevalence and prognostic significance of neuroendocrine cells in esophageal adenocarcinoma. Mod Pathol; 2000 May;13(5):475-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Medical records were reviewed for tumor stage, response to therapy, and patient survival.
  • Thirty-two patients received radiation and chemotherapy, and four received radiation.
  • Tumors with CG-positive cells were moderately to poorly differentiated, and many consisted of large cribriform glands, similar to intestinal-type adenocarcinomas.
  • Neuroendocrine differentiation was retained in lymph node metastases in two cases but lost in three other cases.
  • In 10 CG-negative primary tumors, lymph node metastases were also negative.
  • There was no difference in tumor stage at surgery or survival time between CG-positive and CG-negative tumors.
  • [MeSH-minor] Barrett Esophagus / metabolism. Barrett Esophagus / pathology. Cell Differentiation. Chromogranins / analysis. Humans. Immunohistochemistry. Neoplasm Staging. Neurosecretory Systems / pathology. Prevalence. Prognosis. Survival Analysis. Tennessee / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10824917.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 68485
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Chromogranins
  •  go-up   go-down


5. Fujiwara K, Suzuki S, Yoden E, Ishikawa H, Imajo Y, Kohno I: Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy. Int J Gynecol Cancer; 2002 May-Jun;12(3):250-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy.
  • The purpose of this paper is to prospectively evaluate the effects of local radiation therapy upon localized ovarian cancer following chemotherapy.
  • Patients with objective relapses or refractory disease but with localized epithelial ovarian cancers and who had undergone at least one regimen of chemotherapy were enrolled in this study.
  • The interval between previous chemotherapy and radiation therapy was 4.5 months.
  • The irradiation dose was 52.3 +/- 8.3 Gy.
  • Neither hematologic nor intestinal toxicity >grade 3 was observed.
  • Forty-four disease sites, including the lymph nodes, vaginal cuff, pelvis, abdomen, subcutaneous regions, and the brain were irradiated.
  • Smaller lesions (P = 0.024) and lymph nodes (P = 0.042) demonstrated better responses than larger lesions or other sites, respectively.
  • Regression rates correlated with longer survivals (P = 0.0195) after radiation therapy.
  • Survival was significantly better when radiation therapy was given before patients had symptoms (P = 0.001).
  • Survival was also better in patients with lymph node disease only (P = 0.0069).
  • We conclude that local radiation therapy may be one of the treatment options for relapsed or refractory but localized ovarian cancer, particularly when the tumor is small and/or located in the lymph nodes, even when patients had no symptoms.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Neoplasm Recurrence, Local / radiotherapy. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / radiotherapy. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radiotherapy. Adult. Aged. Carcinoma / drug therapy. Carcinoma / pathology. Carcinoma / radiotherapy. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / radiotherapy. Combined Modality Therapy. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / radiotherapy. Female. Humans. Middle Aged. Neoplasm Staging. Neoplasms, Glandular and Epithelial / drug therapy. Neoplasms, Glandular and Epithelial / pathology. Neoplasms, Glandular and Epithelial / radiotherapy. Pilot Projects. Prognosis. Prospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12060445.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Mejia A, Schulz S, Hyslop T, Weinberg DS, Waldman SA: GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients. Expert Rev Mol Diagn; 2009 Nov;9(8):777-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most important prognostic marker of survival and predictive marker of response to adjuvant chemotherapy in colon cancer patients is tumor cells in regional lymph nodes.
  • Despite their importance, standard techniques to assess nodal metastases remain imperfect, as approximately 30% of patients with histology-negative lymph nodes (pN0) die of recurrent disease, reflecting occult metastases that escape detection.
  • These observations highlight the clinical need for novel, accurate approaches to detect occult lymph node metastases in patients with colon cancer.
  • GUCY2C is a biomarker whose expression normally is restricted to intestinal cells, but is near universally overexpressed by colorectal cancer cells.
  • Recently, a prospective, multicenter, blinded clinical trial demonstrated for the first time that the prognostic utility of GUCY2C quantitative reverse transcriptase (qRT)-PCR to detect occult lymph node metastases in pN0 colorectal cancer patients.
  • The presence of occult lymph node metastases was the strongest independent predictor of time to recurrence and disease-free survival.
  • These observations establish the utility of molecular detection of occult lymph node metastases for estimating prognostic risk in pN0 colorectal cancer patients.
  • Advancing this molecular diagnostic into staging paradigms in clinical laboratories will require validation in independent patient populations, definition of the relationship between the quantity of occult tumor metastases and risk, and determination of the utility of GUCY2C qRT-PCR to identify pN0 patients who might benefit from adjuvant chemotherapy.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Nutr. 1979 Jan;32(1):189-96 [32766.001]
  • [Cites] Cancer. 1980 Jun 15;45(12):2969-74 [7388740.001]
  • [Cites] J Infect Dis. 1980 Aug;142(2):220-8 [6106030.001]
  • [Cites] Biochim Biophys Acta. 1980 Sep 17;632(1):35-46 [6106508.001]
  • [Cites] Cancer. 1981 Mar 15;47(6):1424-9 [7226068.001]
  • [Cites] Br J Surg. 1984 Aug;71(8):604-10 [6743980.001]
  • [Cites] Ann Surg. 1984 Dec;200(6):685-90 [6508395.001]
  • [Cites] J Biol Chem. 1986 Jan 25;261(3):1470-6 [3944095.001]
  • [Cites] Pediatr Res. 1986 Jun;20(6):555-60 [2872650.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):603-10 [3731019.001]
  • [Cites] Pediatr Res. 1987 Jun;21(6):551-5 [2885801.001]
  • [Cites] Dig Dis Sci. 1987 Sep;32(9):1017-26 [3304888.001]
  • [Cites] Arch Surg. 1987 Nov;122(11):1253-6 [3675188.001]
  • [Cites] Gastroenterology. 1988 Feb;94(2):367-73 [2891585.001]
  • [Cites] J Clin Oncol. 1988 Jan;6(1):119-27 [2826712.001]
  • [Cites] Am J Physiol. 1987 Dec;253(6 Pt 1):G775-80 [2892417.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1171-6 [2599905.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] Cell. 1990 Nov 30;63(5):941-8 [1701694.001]
  • [Cites] N Engl J Med. 1991 Mar 14;324(11):709-15 [1997835.001]
  • [Cites] Surg Gynecol Obstet. 1992 Jan;174(1):27-32 [1729745.001]
  • [Cites] Mol Microbiol. 1993 May;8(5):865-73 [8102772.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • [Cites] Cancer. 1994 Feb 1;73(3):563-9 [7507795.001]
  • [Cites] Gastroenterology. 1994 Dec;107(6):1653-61 [7958675.001]
  • [Cites] Lancet. 1995 May 20;345(8960):1255-6 [7746053.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):984-93 [7657129.001]
  • [Cites] Semin Oncol. 1995 Oct;22(5):472-87 [7570058.001]
  • [Cites] Cancer. 1996 Jul 1;78(1):1-3 [8646703.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14827-32 [8962140.001]
  • [Cites] Lab Invest. 1998 Jan;78(1):101-8 [9461126.001]
  • [Cites] Dis Colon Rectum. 1998 Mar;41(3):310-5 [9514425.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Jun;7(6):505-14 [9641495.001]
  • [Cites] N Engl J Med. 1998 Jul 23;339(4):223-8 [9673300.001]
  • [Cites] Dis Colon Rectum. 1999 Feb;42(2):143-54; discussion 154-8 [10211489.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] Dis Colon Rectum. 1999 Aug;42(8):1046-52 [10458129.001]
  • [Cites] Br J Cancer. 1958 Sep;12(3):309-20 [13596482.001]
  • [Cites] CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308 [15537574.001]
  • [Cites] N Engl J Med. 2005 Feb 3;352(5):476-87 [15689586.001]
  • [Cites] Hum Pathol. 2005 Feb;36(2):170-9 [15754294.001]
  • [Cites] Pharm Res. 2005 Apr;22(4):499-511 [15846456.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Sep;5(5):701-13 [16149873.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):11129-35 [16322263.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8549-56 [16361536.001]
  • [Cites] Pharm Res. 2006 Feb;23(2):312-28 [16397743.001]
  • [Cites] Ann Surg Oncol. 2006 Jun;13(6):887-98 [16614880.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4545-52 [16899600.001]
  • [Cites] Nat Rev Drug Discov. 2006 Nov;5(11):897-902 [17080026.001]
  • [Cites] Ann Surg Oncol. 2006 Nov;13(11):1386-92 [17009147.001]
  • [Cites] Semin Oncol. 2006 Dec;33(6 Suppl 11):S42-5 [17178286.001]
  • [Cites] Clin Pharmacol Ther. 2007 Jan;81(1):104-7 [17186007.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Nat Protoc. 2006;1(3):1559-82 [17406449.001]
  • [Cites] Semin Oncol. 2007 Apr;34(2 Suppl 1):S37-40 [17449351.001]
  • [Cites] CA Cancer J Clin. 2007 May-Jun;57(3):168-85 [17507442.001]
  • [Cites] J Natl Cancer Inst. 2007 Jul 4;99(13):998-1003 [17596575.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):599-607 [17681179.001]
  • [Cites] Clin Pharmacol Ther. 2007 Oct;82(4):441-7 [17687268.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):568-75; discussion 575-7 [17893493.001]
  • [Cites] J Mol Diagn. 2007 Nov;9(5):563-71 [17916603.001]
  • [Cites] Am J Pathol. 2007 Dec;171(6):1847-58 [17974601.001]
  • [Cites] Lancet. 2007 Dec 15;370(9604):2020-9 [18083404.001]
  • [Cites] Stat Med. 2007 Dec 30;26(30):5596-611 [17968873.001]
  • [Cites] J Surg Oncol. 2007 Dec 15;96(8):671-7 [18081169.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2008;48:631-51 [17937595.001]
  • [Cites] Clin Pharmacol Ther. 2008 Feb;83(2):199-202 [18202681.001]
  • [Cites] Carcinogenesis. 2008 Aug;29(8):1601-7 [18566015.001]
  • [Cites] AAPS J. 2008 Jun;10(2):401-9 [18686043.001]
  • [Cites] JAMA. 2009 Feb 18;301(7):745-52 [19224751.001]
  • [Cites] Future Oncol. 2009 May;5(4):509-22 [19450179.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3677-83 [19470929.001]
  • [Cites] Clin Transl Sci. 2008 Sep;1(2):163-7 [19727435.001]
  • [Cites] Ann Intern Med. 1999 Dec 7;131(11):805-12 [10610624.001]
  • [Cites] Eur J Cancer. 2000 Mar;36(5):559-66 [10738119.001]
  • [Cites] Cancer. 2000 May 15;88(10):2398-424 [10820364.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jun 24;273(1):225-30 [10873591.001]
  • [Cites] Pharmacol Rev. 2000 Sep;52(3):375-414 [10977868.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5151-7 [11016642.001]
  • [Cites] Expert Opin Pharmacother. 2000 May;1(4):737-55 [11249513.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3124-30 [11306497.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7846-51 [11438734.001]
  • [Cites] J Clin Oncol. 2001 Oct 1;19(19):3951-9 [11579116.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4352-63 [12154040.001]
  • [Cites] Dis Markers. 2002;18(2):41-6 [12364809.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2169-78 [12466132.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71 [12513963.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2695-9 [12594332.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2912-9 [12885809.001]
  • [Cites] Kidney Int. 2004 Jan;65(1):40-53 [14675035.001]
  • [Cites] Mod Pathol. 2004 Apr;17(4):402-6 [14976530.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3395-407 [15199087.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Surg Gynecol Obstet. 1977 Nov;145(5):682-4 [910210.001]
  • [Cites] Nature. 1978 Feb 23;271(5647):755-6 [203862.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Jun;75(6):2800-4 [26915.001]
  • (PMID = 19895223.001).
  • [ISSN] 1744-8352
  • [Journal-full-title] Expert review of molecular diagnostics
  • [ISO-abbreviation] Expert Rev. Mol. Diagn.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / K30 RR022299-10; United States / NCI NIH HHS / CA / R21 CA112147; United States / NIGMS NIH HHS / GM / T32 GM008562-13; United States / NCI NIH HHS / CA / CA75123; United States / NCRR NIH HHS / RR / K30 RR022299; United States / NCRR NIH HHS / RR / RR022299-10; United States / NCI NIH HHS / CA / R01 CA075123-03A1; United States / NIGMS NIH HHS / GM / T32 GM08562; United States / NCI NIH HHS / CA / R01 CA075123-05; United States / NCRR NIH HHS / RR / K30 RR022299-08; United States / NCI NIH HHS / CA / R01 CA075123-04; United States / NIGMS NIH HHS / GM / T32 GM008562-15; United States / NCI NIH HHS / CA / R01 CA095026-02; United States / NCI NIH HHS / CA / R01 CA075123-07; United States / NCI NIH HHS / CA / R01 CA095026-03; United States / NCRR NIH HHS / RR / RR022299-08; United States / NIGMS NIH HHS / GM / T32 GM008562-14; United States / NIGMS NIH HHS / GM / GM008562-15; None / None / / R01 CA095026-02; United States / NCI NIH HHS / CA / R01 CA095026-01A2; United States / NIGMS NIH HHS / GM / T32 GM008562; United States / NCI NIH HHS / CA / R01 CA075123-02; United States / NIGMS NIH HHS / GM / GM008562-13; United States / NCI NIH HHS / CA / R01 CA095026-04; None / None / / R01 CA075123-02; United States / NCI NIH HHS / CA / R01 CA095026; United States / NCRR NIH HHS / RR / RR022299-09; United States / NCI NIH HHS / CA / CA95026; United States / NCI NIH HHS / CA / R01 CA075123-06; United States / NCI NIH HHS / CA / R01 CA095026-05; United States / NIGMS NIH HHS / GM / GM008562-14; United States / NCI NIH HHS / CA / R01 CA075123; United States / NCI NIH HHS / CA / R33 CA112147; United States / NCI NIH HHS / CA / R01 CA095026-06; United States / NCRR NIH HHS / RR / K30 RR022299-09; United States / NHLBI NIH HHS / HL / K30 HL004522; United States / NCI NIH HHS / CA / CA112147
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Peptide; EC 4.6.1.2 / Guanylate Cyclase; EC 4.6.1.2 / Receptors, Guanylate Cyclase-Coupled; EC 4.6.1.2 / enterotoxin receptor
  • [Other-IDs] NLM/ NIHMS169072; NLM/ PMC2810399
  •  go-up   go-down


7. Park ES, Do IG, Park CK, Kang WK, Noh JH, Sohn TS, Kim S, Kim MJ, Kim KM: Cyclooxygenase-2 is an independent prognostic factor in gastric carcinoma patients receiving adjuvant chemotherapy and is not associated with EBV infection. Clin Cancer Res; 2009 Jan 1;15(1):291-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 is an independent prognostic factor in gastric carcinoma patients receiving adjuvant chemotherapy and is not associated with EBV infection.
  • EXPERIMENTAL DESIGN: Tissue microarray samples from 457 gastric carcinoma patients who underwent gastrectomy and adjuvant chemotherapy were studied with EBER1 in situ hybridization for EBV and immunohistochemistry for COX-2 and other gastric carcinoma-related proteins (hMLH1, E-cadherin, c-erbB, and cyclin D1).
  • RESULTS: EBV infection was observed in 10.9% of gastric carcinomas and was associated with proximal tumor location, increased numbers of lymph node, and E-cadherin expression (P < 0.01).
  • COX-2 overexpression was closely associated with intestinal histologic type and lower tumor stage (P = 0.01).
  • Univariate analysis showed that pT, pN, lymph node ratio, American Joint Committee on Cancer stage, numbers of negative lymph nodes, and resection margin <1 cm were significant prognostic factors.
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Tissue Array Analysis


8. Zheng HC, Li XH, Hara T, Masuda S, Yang XH, Guan YF, Takano Y: Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas. Virchows Arch; 2008 May;452(5):525-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas.
  • To investigate the pathobiological behaviors of gastric mixed-type (MT) carcinomas and gastric carcinogenesis, the clinicopathological characteristics of MT carcinomas were analyzed and compared with intestinal-type (IT) and diffuse-type (DT) carcinomas.
  • The expression of Ki-67, caspase-3, p53, fragile histine triad (FHIT), maspin, extracellular matrix metalloproteinase inducer (EMMPRIN), vascular growth factor (VEGF), MUC-2, 4, 5AC and 6, CD44, E-cadherin, beta-catenin, and phosphorylated glycogen synthase kinase 3beta-ser9 (P-GSK3beta-ser9) was examined on tissue microarrays using immunohistochemistry.
  • It was found that MT carcinomas exhibited large size, deep invasion, frequent local invasion, and lymph node metastasis in comparison with IT and DT carcinomas (p < 0.05).
  • All the markers except MUC-5AC showed higher expression in IT than DT carcinomas (p < 0.05).
  • The expression of maspin, EMMPRIN, VEGF, MUC-4, and membrane E-cadherin was stronger in MT intestinal than diffuse component (p < 0.05).
  • Immunoreactivities to Ki-67, EMMPRIN, and VEGF were weaker in IT carcinoma than in the MT intestinal portion (p < 0.05), while the opposite was true for CD44, MUC-2, and MUC-6 (p < 0.05).
  • The MT diffuse component displayed a higher expression of FHIT, VEGF, and P-GSK3beta-ser9 than DT carcinoma (p < 0.05).
  • The accumulative survival rate of the IT carcinoma patients was higher than the other types (p < 0.05).
  • The invasive depth, venous invasion, lymph node, peritoneal or liver metastasis, and Lauren's classification were independent prognostic factors for gastric carcinomas (p < 0.05).
  • These findings suggested that MT carcinomas were also indicated to be more aggressive than IT and DT carcinomas.
  • Significant differences were observed in the proliferation, apoptosis, angiogenesis, mucin secretion, and cell adhesion between IT and DT carcinomas, whereas only a few of these characteristics showed differences between the MT intestinal and diffuse parts, thus suggesting that both the MT components might originate from the stem cells with similar genetic traits, but follow different histogenic pathways.
  • [MeSH-major] Mixed Tumor, Malignant / diagnosis. Mixed Tumor, Malignant / pathology. Stomach Neoplasms / diagnosis. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Biomarkers, Tumor / metabolism. Cell Adhesion. Cell Proliferation. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Protein Array Analysis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 1995 Jul;191(6):571-84 [7479380.001]
  • [Cites] Oncology. 1995 Jul-Aug;52(4):334-9 [7539903.001]
  • [Cites] Gen Diagn Pathol. 1997 Jul;143(1):39-48 [9269907.001]
  • [Cites] Lab Invest. 1999 Apr;79(4):459-65 [10211998.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Science. 2004 Nov 26;306(5701):1568-71 [15567866.001]
  • [Cites] J Surg Oncol. 2005 Jun 1;90(3):114-33; discussion 133 [15895459.001]
  • [Cites] World J Gastroenterol. 2006 Jan 21;12(3):363-71 [16489634.001]
  • [Cites] Anticancer Res. 2006 May-Jun;26(3B):2353-60 [16821616.001]
  • [Cites] Gastric Cancer. 2006;9(3):177-84 [16952035.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Dec;132(12):817-23 [16807756.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5A):3579-83 [17094486.001]
  • [Cites] Br J Cancer. 2006 Nov 20;95(10):1371-8 [17088917.001]
  • [Cites] J Clin Pathol. 2007 Mar;60(3):273-7 [16714395.001]
  • [Cites] Anticancer Res. 2007 Jan-Feb;27(1A):259-65 [17352241.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):432-40 [18091387.001]
  • [Cites] J Pathol. 2000 Mar;190(4):437-43 [10699992.001]
  • [Cites] Br J Surg. 2000 May;87(5):618-26 [10792320.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jan;10(1):75-8 [11205493.001]
  • [Cites] Chem Rev. 2001 Aug;101(8):2527-40 [11749387.001]
  • [Cites] Histopathology. 2002 Jul;41(1):56-64 [12121238.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Nov;17(11):1165-9 [12453275.001]
  • [Cites] J Clin Epidemiol. 2003 Jan;56(1):1-9 [12589864.001]
  • [Cites] World J Gastroenterol. 2003 Jul;9(7):1415-20 [12854132.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):77-99 [15000151.001]
  • [Cites] IARC Sci Publ. 2004;(157):327-49 [15055305.001]
  • [Cites] J Pathol. 2004 Jun;203(2):681-7 [15141383.001]
  • [Cites] Gastric Cancer. 2004;7(2):61-77 [15224192.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1141-9 [15167936.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1989 Jan;11(1):37-40 [2550197.001]
  • [Cites] Cancer. 1990 May 1;65(9):2086-90 [2372774.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;120(1-2):103-11 [7903667.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):112-21 [9036879.001]
  • (PMID = 18266006.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2329735
  •  go-up   go-down


9. Lerouge D, Touboul E, Lefranc JP, Uzan S, Jannet D, Moureau-Zabotto L, Genestie C, Antoine M, Jamali M: [Preoperative concurrent radiation therapy and chemotherapy for operable bulky carcinomas of uterine cervix stages IB2, IIA, and IIB with proximal parametrial invasion]. Cancer Radiother; 2004 Jun;8(3):168-77
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preoperative concurrent radiation therapy and chemotherapy for operable bulky carcinomas of uterine cervix stages IB2, IIA, and IIB with proximal parametrial invasion].
  • [Transliterated title] Association concomitante préopératoire de radiothérapie et de chimiothérapie dans les cancers du col utérin opérables de stades IB2, IIA et IIB proximal de gros volume.
  • A clinical pelvic lymph node involvement has been observed in 10 pts.
  • All patients underwent preoperative external beam pelvic radiation therapy (EBPRT) and concomitant chemotherapy during the first and the fourth radiation weeks combining 5-fluorouracil and cisplatin.
  • The pelvic dose was 40.50 Gy over 4.5 weeks.
  • EBPRT was followed by low-dose-rate uterovaginal brachytherapy with a total dose of 20 Gy in 17 pts.
  • Para-aortic lymphadenectomy was performed in eight pts without pathologic para-aortic lymph node involvement.
  • Twenty-one of 25 pts who had not received preoperative uterovaginal brachytherapy underwent postoperative low-dose-rate vaginal brachytherapy of 20 Gy.
  • RESULTS: Pathologic residual tumour or lymph node involvement was observed in 23 pts.
  • Four pts had pathologic lymph node involvement, three pts had vaginal residual tumour, and four pts had pathologic parametrial invasion.
  • However, six pts had grade 3 acute intestinal toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / radiotherapy. Neoplasm Invasiveness. Neoplasm Staging. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Brachytherapy. Cisplatin / administration & dosage. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Middle Aged. Neoadjuvant Therapy. Radiation Injuries. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15217584.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Ishihara S, Honda Y, Asato T, Nonaka M, Nakagawa S, Hirashima K, Hayashi N, Baba H, Iyama K: Interdigitating dendritic cell sarcoma of the ileum recurred in multiple lymph nodes and duodenum three years after operation without chemotherapy. Pathol Res Pract; 2010 Jul 15;206(7):514-8
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interdigitating dendritic cell sarcoma of the ileum recurred in multiple lymph nodes and duodenum three years after operation without chemotherapy.
  • At that time, a pathologic diagnosis of malignant peripheral nerve sheath tumor was made.
  • The patient, who was not treated with chemotherapy, showed no signs of recurrence.
  • Oval to spindle-shaped atypical cells, which resembled ileal tumor cells, infiltrated into the lymph node and duodenum.
  • Based on the histologic and immunohistochemical analysis, the histopathologic diagnosis of IDCS was confirmed.
  • To our knowledge, five cases of IDCS arising in the intestinal tract have been reported to date, and only one case, treated with both surgery and chemotherapy, led to remission.
  • This is the first case that has a comparatively favorable prognosis without chemotherapy after surgery.
  • [MeSH-major] Dendritic Cell Sarcoma, Interdigitating / pathology. Duodenal Neoplasms / pathology. Ileal Neoplasms / pathology. Lymph Nodes / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Diagnostic Errors. Digestive System Surgical Procedures. Humans. Immunohistochemistry. Male. Middle Aged. Nerve Sheath Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20399026.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  •  go-up   go-down


11. Fonteyne V, De Gersem W, De Neve W, Jacobs F, Lumen N, Vandecasteele K, Villeirs G, De Meerleer G: Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer. Int J Radiat Oncol Biol Phys; 2009 Nov 15;75(4):1013-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
  • PURPOSE: To determine the planning results and acute toxicity after hypofractionated intensity-modulated arc radiotherapy and androgen deprivation for lymph node metastasized (Stage N1) prostate cancer.
  • METHODS AND MATERIALS: A total of 31 patients with Stage T1-T4N1M0 prostate cancer were treated with intensity-modulated arc radiotherapy and 3 years of androgen deprivation as primary treatment.
  • Elective lymph node areas ((e)) were delineated and expanded by 2 mm to create the CTV(e).
  • A median dose of 69.3 Gy and 50 Gy was prescribed to the PTV(p) and PTV(e) respectively, to be delivered in 25 fractions.
  • Upper and lower gastrointestinal toxicity was scored using the Radiation Therapy Oncology Group toxicity and radiotherapy-induced lower intestinal toxicity scoring system.
  • Genitourinary toxicity was scored using a combined Radiation Therapy Oncology Group, LENT-SOMA (late effects normal tissue-subjective, objective, management, analytic), and Common Toxicity Criteria toxicity scoring system.
  • RESULTS: The median follow-up time was 3 months.
  • The mean prescription dose to the CTV(p) and PTV(p) was 70.4 Gy and 68.6 Gy, respectively.
  • The minimal dose to the CTV(e) and PTV(e) was 49.0 Gy and 47.0 Gy, respectively.
  • Fourteen patients developed acute Grade 2 lower gastrointestinal toxicity.
  • Acute Grade 3 and 2 genitourinary toxicity developed in 2 and 14 patients, respectively.
  • CONCLUSION: The results of our study have shown that hypofractionated intensity-modulated arc radiotherapy as primary therapy for N1 prostate cancer is feasible with low toxicity.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / adverse effects
  • [MeSH-minor] Aged. Dose Fractionation. Follow-Up Studies. Humans. Intestine, Large / radiation effects. Intestine, Small / radiation effects. Lymphatic Metastasis / radiotherapy. Male. Middle Aged. Neoplasm Staging. Prostate / radiation effects. Radiation Injuries / pathology. Radiotherapy Planning, Computer-Assisted. Seminal Vesicles / radiation effects. Tumor Burden. Urogenital System / radiation effects

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19386427.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists
  •  go-up   go-down


12. Lee J, Kim WS, Kim K, Ahn JS, Jung CW, Lim HY, Kang WK, Park K, Ko YH, Kim YH, Park C, Yoon SH, Lee WY, Chun HK: Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma. Leuk Res; 2007 Mar;31(3):359-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma.
  • This study aimed to assess the efficacy of surgical treatment followed by post-surgical CHOP chemotherapy and to analyze the impact of T and N stage on survival in localized intestinal diffuse large B cell lymphoma (DLBL) patients.
  • A prospective non-randomized study was conducted and 40 patients received primary surgical resection with lymph node dissection and post-operative CHOP chemotherapy.
  • Primary surgical resection followed by post-operative CHOP chemotherapy showed high efficacy in intestinal DLBL patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / surgery. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / surgery. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prednisolone / therapeutic use. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Res. 2007 Mar;31(3):287-9 [17010434.001]
  • (PMID = 16930692.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


13. Stein HJ, Feith M, Siewert JR: [Neoadjuvant therapy in the upper gastro-intestinal tract. Modern strategies for Barrett's cancer]. Chirurg; 2009 Nov;80(11):1019-22
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant therapy in the upper gastro-intestinal tract. Modern strategies for Barrett's cancer].
  • [Transliterated title] Neoadjuvante Therapie im oberen Gastrointestinaltrakt. Aktuelle Konzepte beim Barrett-Karzinom.
  • While primary surgical resection with systematic lymphadenectomy remains the treatment of choice for locoregional Barrett's cancer, neoadjuvant chemotherapy is an increasingly accepted treatment modality for patients with locally advanced tumors and patients with extensive lymphatic spread.
  • In contrast to neoadjuvant radiochemotherapy preoperative chemotherapy alone does not seem to increase peri-operative complications and mortality.
  • Responders to pre-operative treatment clearly have a survival advantage as compared to those who do not respond.
  • The use of positron emission tomography to measure changes in glucose metabolism of the primary tumor can predict response early after initiation of neoadjuvant chemotherapy and thus help to select patients who will or will not benefit from this approach.
  • The best treatment strategy for non-responders to neoadjuvant therapy remains to be defined.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / surgery. Esophageal Neoplasms / surgery. Esophagectomy. Lymph Node Excision. Neoadjuvant Therapy. Precancerous Conditions / surgery
  • [MeSH-minor] Blood Glucose / metabolism. Combined Modality Therapy. Disease-Free Survival. Fluorodeoxyglucose F18. Humans. Lymphatic Metastasis / pathology. Neoplasm Staging. Positron-Emission Tomography. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2004 Jul;53(7):925-30 [15194636.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):624-8; discussion 628-31 [17893499.001]
  • [Cites] Future Oncol. 2006 Dec;2(6):717-21 [17155898.001]
  • [Cites] World J Surg. 2005 Aug;29(8):940-8 [15988623.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12 ):3058-65 [11408502.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):797-805 [17693134.001]
  • [Cites] Eur J Cancer. 2008 Sep;44(13):1807-19 [18640028.001]
  • [Cites] Lancet Oncol. 2007 Mar;8(3):226-34 [17329193.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4692-8 [16966684.001]
  • [Cites] Dis Esophagus. 2008;21(7):601-6 [18430179.001]
  • [Cites] Lancet Oncol. 2007 Mar;8(3):189-90 [17329188.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] Surg Clin North Am. 2000 Apr;80(2):659-82; discussions 683-6 [10836011.001]
  • [Cites] J Surg Oncol. 2005 Dec 1;92(3):210-7 [16299789.001]
  • [Cites] World J Surg. 2003 Sep;27(9):1052-7 [12917758.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):851-6 [19139439.001]
  • [Cites] Chirurg. 2005 Jun;76(6):588-94 [15875146.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Ann Surg Oncol. 2009 Apr;16(4):878-86 [19194759.001]
  • (PMID = 19902287.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Blood Glucose; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 20
  •  go-up   go-down


14. Ott K, Lordick F: [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint]. Chirurg; 2009 Nov;80(11):1028-34
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint].
  • [Transliterated title] Neoadjuvante Therapie im oberen Gastrointestinaltrakt. Magenkarzinom aus chirurgischer Sicht.
  • It has been shown that multimodal treatment can improve the outcome in comparison to surgery alone.
  • Two randomized studies that have been performed in Europe have shown that peri-operative chemotherapy significantly improves the survival of patients with adenocarcinoma of the stomach and of the gastro-esophageal junction.
  • These results have a profound effect on the treatment of patients presenting with stage II or stage III disease.
  • After neoadjuvant chemotherapy patients should undergo a D-2 lymphadenectomy due to the high probability of lymph node metastasis.
  • Neither mortality nor complication rate are increased after neoadjuvant chemotherapy for gastric cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Esophagogastric Junction. Neoadjuvant Therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Cooperative Behavior. Disease-Free Survival. Hospitals, University. Humans. Interdisciplinary Communication. Lymph Node Excision. Lymphatic Metastasis. Neoplasm Staging. Patient Care Team. Prognosis. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3719-25 [17704421.001]
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Int J Cancer. 2006 Dec 15;119(12):2885-94 [16929515.001]
  • [Cites] Lancet Oncol. 2006 Apr;7(4):309-15 [16574546.001]
  • [Cites] Clin Cancer Res. 2008 Apr 1;14 (7):2012-8 [18381939.001]
  • [Cites] Chirurg. 2006 Nov;77(11):971-80 [17066269.001]
  • [Cites] Chirurg. 2007 Sep;78(9):792-801 [17676284.001]
  • [Cites] Gastric Cancer. 2005;8(1):1-5 [15747167.001]
  • [Cites] Ann Surg Oncol. 2009 Apr;16(4):1017-25 [19189186.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):1-8 [17592282.001]
  • [Cites] Chirurg. 2006 Mar;77(3):227-35 [16511688.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1521-30 [14508841.001]
  • [Cites] Radiology. 2006 May;239(2):472-80 [16543584.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5095-102 [17785563.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):303-8 [10077040.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):797-805 [17693134.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4692-8 [16966684.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2307-15 [12796400.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2069-77 [15082726.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4604-10 [14673049.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):808-16 [15492562.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):453-62 [18669424.001]
  • [Cites] Gastric Cancer. 2008;11(1):1-9 [18373171.001]
  • [Cites] Lancet Oncol. 2006 Aug;7(8):644-51 [16887481.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] J Am Coll Surg. 2007 Oct;205(4):593-601 [17903735.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Chirurg. 1999 May;70(5):520-9 [10412596.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • (PMID = 19756431.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 30
  •  go-up   go-down


15. Takashima T, Ito T, Sato T, Hirata K: [A case of S-1-resistant recurrent gastric cancer successfully treated with weekly administration of paclitaxel]. Gan To Kagaku Ryoho; 2007 Jul;34(7):1103-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of recurrent gastric cancer with peritoneal dissemination and paraaortic lymph node metastases, successfully treated with weekly administration of paclitaxel.
  • The patient was a 63-year-old man who underwent distal gastrectomy with lymph node dissection for advanced gastric cancer in February 2005.
  • After the operation, adjuvant chemotherapy with S-1 was started and continued.
  • Clinical symptoms were relieved, and abdominal X-ray findings showing intestinal obstruction disappeared after 2 courses.
  • CT scan revealed metastatic lymph nodes were reduced after 3 courses.
  • Weekly administration of PTX may be a promising regimen as second-line chemotherapy for S-1-resistant recurrent gastric cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Drug Resistance, Neoplasm. Oxonic Acid. Paclitaxel / administration & dosage. Stomach Neoplasms / drug therapy. Tegafur
  • [MeSH-minor] Chemotherapy, Adjuvant. Drug Administration Schedule. Drug Combinations. Gastrectomy. Humans. Leukopenia / chemically induced. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Peripheral Nervous System Diseases / chemically induced

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637549.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


16. Shirakawa T, Tanaka N, Yokoi K, Ishikawa N, Seya T, Horiba K, Yamada T, Kanazawa Y, Okawa K, Yoshioka M, Oaki Y, Tokunaga A, Tajiri T: [A case of advanced gastric cancer successfully treated by TS-1 and CDDP after jejunostomy]. Gan To Kagaku Ryoho; 2006 Jun;33(6):811-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One course consisted of TS-1 (80 mg/day) via an intestinal fistula tube from days 1 to 14 followed by 14 days rest and CDDP (80 mg/day) was administered by 24-hour continuous intravenous infusion on day 8.
  • After 3 courses, the primary tumor and lymph node metastases decreased in size (PR), and CT scan showed the multiple lung metastases had disappeared.
  • Total gastrectomy (D 2) and splenectomy were performed after chemotherapy.
  • The final diagnosis was Stage IIIA and the pathological response to chemotherapy was Grade 2.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Jejunostomy. Splenectomy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Female. Humans. Infusions, Parenteral / methods. Lung Neoplasms / secondary. Lymph Nodes / pathology. Lymphatic Metastasis. Neoplasm Invasiveness. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Remission Induction. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770103.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


17. Grundmann RT, Hölscher AH, Bembenek A, Bollschweiler E, Drognitz O, Feuerbach S, Gastinger I, Hermanek P, Hopt UT, Hünerbein M, Illerhaus G, Junginger T, Kraus M, Meining A, Merkel S, Meyer HJ, Mönig SP, Piso P, Roder J, Rödel C, Tannapfel A, Wittekind C, Woeste G: [Diagnosis of and therapy for gastric cancer--work-flow]. Zentralbl Chir; 2009 Aug;134(4):362-74
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis of and therapy for gastric cancer--work-flow].
  • [Transliterated title] Diagnostik und Therapie des Magenkarzinoms--Workflow.
  • AIM: This review comments on the diagnosis and treatment of gastric cancer in the classical meaning--excluding adenocarcinoma of the -oesophagogastric junction.
  • Algorithms of diagnosis and care with respect to tumour stage are presented.
  • PREOPERATIVE DIAGNOSIS: Besides oesophagogastroduodenoscopy, endoscopic ultrasonography is necessary for the accurate diagnosis of T categories and as a selection criterion for neoadjuvant chemotherapy.
  • Computed tomography is recommended for preoperative evaluation of tumours > T1, laparoscopy has become an effective stag-ing tool in T3 and T4 tumours avoiding unnecessary laparotomies and improving the detection of small -liver and peritoneal metastases.
  • TREATMENT: Endoscopic mucosal resection and submucosal dissection are indicated in superficial cancer confined to the mucosa with special characteristics (T1 a / no ulcer / G1, 2 / Laurén intestinal / L0 / V0 / tumour size < 2 cm).
  • In all other cases total gastrectomy or distal subtotal gastric resection are indicated, the latter in cases of tumours located in the distal two-thirds of the stomach.
  • Standard lymphadenectomy (LAD) is the D2 LAD without distal pancreatectomy and splenectomy.
  • The Roux-en-Y oesophagojejunostomy is still the preferred type of reconstruction.
  • Perioperative chemotherapy and postoperative chemoradiotherapy are based on the MAGIC and MacDonald trials.
  • Perioperative chemotherapy should be performed in patients with T3 and T4 tumours with the aim to increase the likelihood of curative R0-resection by downsizing the tumour.
  • Adjuvant postoperative chemotherapy cannot be recommended since its benefit has so far not been proven in randomised trials.
  • In selected patients with incomplete lymph-node dissection and questionable R0-resection postoperative chemoradiotherapy may be debated.
  • [MeSH-major] Gastrectomy. Lymph Node Excision. Stomach Neoplasms / diagnosis. Stomach Neoplasms / surgery
  • [MeSH-minor] Biopsy. Carcinoma in Situ / diagnosis. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Disease-Free Survival. Gastric Mucosa / pathology. Gastric Mucosa / surgery. Gastroscopy. Humans. Laparoscopy. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lymph Nodes / pathology. Neoplasm Invasiveness / pathology. Neoplasm Staging. Palliative Care. Perioperative Care. Peritoneal Lavage. Prognosis. Stomach / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag Stuttgart.New York.
  • (PMID = 19688686.001).
  • [ISSN] 1438-9592
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 109
  •  go-up   go-down


18. Stroh C, Manger T: [Primary amelanotic anorectal melanoma--a case report]. Zentralbl Chir; 2007 Dec;132(6):560-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Das primäre amelanotische Melanom des Rektums - Ein Fallbericht.
  • Therefore transrectal ultrasound is of major importance in the preoperative staging and postoperative follow-up especially in diagnosis of local recurrence by using the ultrasound-guided, transrectal aspiration.
  • The overall survival time is 10 months after diagnosis.
  • 7 months after a wide local excision of the tumour and interferon therapy in case of the absence of pararectal, inguinal metastases and other metastases the patient developed pararectal metastasis.
  • An abdominoperineal resection and resection of inguinal lymph nodes was performed.
  • Two months later paraaortal lymph nodes were detected.
  • We started chemotherapy with Dacarbazin and with regard of the tumour progress the chemotherapy was changed to Vindesin 25 months after first operation supported by a radiotherapy with 40 Gray.
  • The patient died 36 months after diagnosis.
  • CONCLUSION: The prognosis of primary malignant anorectal melanoma is poor, irrespective of surgical treatment.
  • Chemotherapy, radiotherapy and immunotherapy should be considered in the treatment of anorectal melanoma to influence the overall survival.
  • [MeSH-minor] Chemotherapy, Adjuvant. Disease Progression. Endosonography. Fatal Outcome. Female. Follow-Up Studies. Humans. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Intestinal Mucosa / ultrasonography. Lymph Node Excision. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Recurrence, Local / ultrasonography. Neoplasm Staging. Palliative Care. Proctoscopy. Radiotherapy, Adjuvant. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18098086.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Stein HJ, Feith M, Siewert JR: Cancer of the esophagogastric junction. Surg Oncol; 2000 Jul;9(1):35-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epidemiological, clinical and pathological data support a sub-classification of adenocarcinomas arising in the vicinity of the esophagogastric junction (AEG) into adenocarcinoma of the distal esophagus (Type I), true carcinoma of the cardia (Type II) and subcardial carcinoma (Type III).
  • While most, if not all, adenocarcinomas of the distal esophagus arise from areas with specialized intestinal metaplasia, which develop as a consequence of chronic gastroesophageal reflux, the etiology and pathogenesis of true carcinoma of the gastric cardia and subcardial gastric cancer is not clear at present.
  • Although a subgroup of true carcinomas of the gastric cardia may also develop within short segments of intestinal metaplasia at the esophagogastric junction, a causal relation between these tumors and gastroesophageal reflux has been difficult to establish.
  • Our experience in the management of more than 1000 such patients during the past 18 years suggests that an individualized therapeutic strategy oriented by tumor type and stage results in survival rates superior to those reported with a more indiscriminate approach.
  • This individualized strategy prescribes a transmediastinal esophagectomy with lymphadenectomy in the lower posterior mediastinum and along the celiac axis for Type I tumors, extended total gastrectomy with transhiatal resection of the distal esophagus and D2 lymphadenectomy for Type II and Type III tumors, a limited resection of the esophagogastric junction and distal esophagus with interposition of a pedicled jejunal segment for uT1N0 tumors, and neoadjuvant chemotherapy followed by resection for uT3/T4 tumors.
  • Extensive preoperative staging is essential to allow correct selection of the appropriate therapeutic strategy using this tailored approach.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / therapy. Esophagogastric Junction. Stomach Neoplasms / diagnosis. Stomach Neoplasms / therapy
  • [MeSH-minor] Algorithms. Combined Modality Therapy. Decision Trees. Esophagectomy. Gastrectomy. Gastroesophageal Reflux / complications. Humans. Incidence. Lymph Node Excision. Neoplasm Staging. Preoperative Care. Prevalence. Splenectomy. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11525305.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 36
  •  go-up   go-down


20. Li JQ, Miki H, Ohmori M, Wu F, Funamoto Y: Expression of cyclin E and cyclin-dependent kinase 2 correlates with metastasis and prognosis in colorectal carcinoma. Hum Pathol; 2001 Sep;32(9):945-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To examine the roles of their expression in the progression of colorectal carcinoma, 21 normal mucosa, 9 hyperplastic polyps, 58 adenomas, 17 adenocarcinoma in adenomas, 203 primary cancers, 21 lymph node metastases, and 10 hepatic metastases were immunohistochemically stained with anti-cyclin E, anti-CDK2, and anti-Ki67 antibodies.
  • From the primary to the lymph node-metastatic foci, cyclin E protein remained unchanged, but CDK2 increased significantly.
  • In primary carcinomas, the reduction of cyclin E was significantly associated with large tumor size, mucinous type, venous invasion, deep infiltration, lymph nodal metastasis, peritoneal metastasis, advanced stage, and poor prognosis.
  • Thus, CDK2 overexpression could facilitate lymph node metastasis.
  • Anti-cyclin E or anti-CDK2 chemotherapy should be targeted to the cancers with such overexpression.
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Aged. Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Colon / metabolism. Colon / pathology. Cyclin-Dependent Kinase 2. Disease-Free Survival. Humans. Hyperplasia. Immunoenzyme Techniques. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Intestinal Polyps / metabolism. Intestinal Polyps / pathology. Ki-67 Antigen / metabolism. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphatic Metastasis. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Survival Rate

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company
  • (PMID = 11567224.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cyclin E; 0 / Ki-67 Antigen; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.22 / CDC2-CDC28 Kinases; EC 2.7.11.22 / CDK2 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 2; EC 2.7.11.22 / Cyclin-Dependent Kinases
  •  go-up   go-down


21. González-Moreno S, Sugarbaker PH: Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. Br J Surg; 2004 Mar;91(3):304-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients had peritoneal seeding at the time of referral and were treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy.
  • The main independent variable for statistical analysis was the surgical procedure used to resect the primary cancer (appendicectomy alone versus right hemicolectomy).
  • RESULTS: Median follow-up after the initial diagnosis was 4 years.
  • The rate of regional lymph node positivity was 5.0 per cent.
  • When the incidence of lymph node metastasis was determined by histological type, it was statistically significantly higher in intestinal (66.7 per cent) than in mucinous (4.2 per cent) tumours (P < 0.001).
  • The presence of lymph node metastases had no influence on prognosis (P = 0.155).
  • The surgical procedure (appendicectomy alone versus right hemicolectomy) had an influence on patient survival by univariate analysis (P < 0.001), but not by multivariate analysis (P = 0.258).
  • These data suggest that right hemicolectomy should be avoided unless metastatic involvement of the appendiceal or distal ileocolic lymph nodes is documented by biopsy, or the resection margin is inadequate.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Appendiceal Neoplasms / surgery. Colectomy / methods. Neoplasm Seeding. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Analysis of Variance. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 British Journal of Surgery Society Ltd.
  • (PMID = 14991630.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. Fabozzi M, Allieta R, Brachet Contul R, Grivon M, Millo P, Lale-Murix E, Nardi M Jr: Comparison of short- and medium-term results between laparoscopically assisted and totally laparoscopic right hemicolectomy: a case-control study. Surg Endosc; 2010 Sep;24(9):2085-91
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: This study aimed to compare the short- and medium-term results obtained by totally laparoscopic right colectomy (TL) with those obtained by laparoscopically assisted right colectomy (LAC) for the treatment of right colon cancer.
  • The study outcomes included operative time, length of minilaparotomy, intraoperative complications, postoperative pain, time to resumption of the gastrointestinal functions, permanence of abdominal drain, analgesic therapy duration, postoperative complications, hospitalization time, number of harvested lymph nodes, and distant metastases onset.
  • RESULTS: The mean operative times were 78 ± 25 min (TL group) and 92 ± 22 min (LAC group) (p < 0.05).
  • The complications included one case of intraoperative small bowel lesion, three cases of postoperative respiratory infections, three cases of anastomotic leakage, two cases of intestinal occlusion, three cases of minilaparotomy infection, one case of postoperative femoral neurosis, one case of postoperative heart attack, and one case of postoperative pancreatitis.
  • The limits of this retrospective comparative study do not allow definitive conclusions to be drawn despite the encouraging data for the next prospective randomized studies.
  • [MeSH-minor] Analgesics / therapeutic use. Drainage / methods. Female. Humans. Intraoperative Complications. Length of Stay / statistics & numerical data. Lymph Node Excision. Male. Middle Aged. Neoplasm Metastasis. Pain, Postoperative / drug therapy. Postoperative Complications. Recovery of Function. Retrospective Studies. Statistics, Nonparametric. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2009 Jan;10(1):44-52 [19071061.001]
  • [Cites] World J Gastroenterol. 2005 Jan 21;11(3):323-6 [15637736.001]
  • [Cites] Surgery. 2006 Oct;140(4):675-82; discussion 682-3 [17011916.001]
  • [Cites] Dis Colon Rectum. 2006 Apr;49(4):464-9 [16518715.001]
  • [Cites] World J Surg Oncol. 2007 May 11;5:49 [17498289.001]
  • [Cites] World J Surg. 2008 Jun;32(6):1138-41 [18404288.001]
  • [Cites] Surg Endosc. 2008 Aug;22(8):1769-80 [18437486.001]
  • [Cites] Minerva Chir. 2003 Aug;58(4):621-7 [14603179.001]
  • [Cites] Curr Opin Crit Care. 2009 Aug;15(4):355-8 [19617822.001]
  • [Cites] Ann Surg Oncol. 2007 Jun;14(6):1878-9 [17377832.001]
  • [Cites] Surg Endosc. 2009 Jul;23(7):1603-8 [19452217.001]
  • [Cites] Am J Surg. 2002 Jun;183(6):630-41 [12095591.001]
  • [Cites] Surg Radiol Anat. 2003 May;25(2):86-8 [12802511.001]
  • [Cites] Surg Clin North Am. 2008 Oct;88(5):1047-72, vii [18790154.001]
  • [Cites] Ann Surg. 2007 Nov;246(5):728-33 [17968162.001]
  • [Cites] Dis Colon Rectum. 2008 Sep;51(9):1350-5 [18478297.001]
  • [Cites] Can J Surg. 2007 Feb;50(1):48-57 [17391617.001]
  • [Cites] Bull Cancer. 2007 Dec;94(12):1053-8 [18156112.001]
  • [Cites] Cochrane Database Syst Rev. 2008 Apr 16;(2):CD003432 [18425886.001]
  • [Cites] Chir Ital. 2008 Jan-Feb;60(1):1-7 [18389741.001]
  • (PMID = 20174945.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Analgesics
  •  go-up   go-down


23. Oi K, Makino M, Ozaki M, Takemoto H, Yamane N, Nakamura S, Ikeguchi M, Kaibara N: Immunohistochemical dihydropyrimidine dehydrogenase expression is a good prognostic indicator for patients with Dukes' C colorectal cancer. Anticancer Res; 2004 Jan-Feb;24(1):273-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Dihydropyrimidine dehydrogenase (DPD) is an enzyme that catabolizes 5-fluorouracil (5-FU), which is widely used for chemotherapy in patients with advanced colorectal cancer (CRC).
  • MATERIALS AND METHODS: We investigated DPD activities in normal mucosa (N) and tumors (T) by enzyme-linked immunosorbent assay (ELISA) in 64 surgically resected patients with Dukes' C CRC who were treated orally with postoperative adjuvant FU-based chemotherapy.
  • Further, tumor DPD activity and immunoreactivity also correlated with lymph node metastatic status (p=0.0409).
  • CONCLUSION: Immunohistochemical DPD expression in tumors is a useful prognostic parameter in patients with Dukes' C CRC treated with postoperative adjuvant FU-based chemotherapy.
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / therapeutic use. Enzyme-Linked Immunosorbent Assay. Female. Fluorouracil / therapeutic use. Humans. Immunohistochemistry. Intestinal Mucosa / enzymology. Male. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15015608.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Overman MJ, Kopetz S, Lin E, Abbruzzese JL, Wolff RA: Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol; 2010 May;49(4):474-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine.
  • BACKGROUND: The benefit of adjuvant therapy for resected small bowel adenocarcinoma has not been proven.
  • We undertook a retrospective analysis to evaluate the benefit of adjuvant therapy in a clearly defined patient population with curatively resected small bowel adenocarcinoma.
  • Thirty patients (56%) received adjuvant therapy consisting of systemic chemotherapy with or without radiation in 28 and radiation alone in two.
  • Patients who received adjuvant therapy had significantly higher tumor stage and rate of lymph node involvement.
  • Five-year DFS and OS did not differ between treatment groups.
  • In multivariate analysis, the use of adjuvant therapy was associated with improved DFS (HR 0.27; 95% CI 0.07-0.98, P = 0.05) but not OS (HR 0.47; 95% CI 0.13-1.62, P = 0.23).
  • In patients with a high risk of relapse (defined as a lymph node ratio >or=10%), adjuvant therapy appeared to improve OS, P = 0.04, but not DFS, P = 0.15.
  • DISCUSSION: The use of adjuvant therapy for curatively resected small bowel adenocarcinoma was associated with an improvement in DFS.
  • This finding strongly supports further investigation of adjuvant chemotherapy in this tumor type.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / therapy. Intestine, Small
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Chemotherapy, Adjuvant. Disease-Free Survival. Duodenal Neoplasms / therapy. Female. Follow-Up Studies. Humans. Ileal Neoplasms / therapy. Jejunal Neoplasms / therapy. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20397775.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


25. Wang HJ, Zhu JS, Zhang Q, Sun Q, Guo H: High level of ezrin expression in colorectal cancer tissues is closely related to tumor malignancy. World J Gastroenterol; 2009 Apr 28;15(16):2016-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High level of ezrin expression in colorectal cancer tissues is closely related to tumor malignancy.
  • AIM: To investigate the ezrin expression in normal colorectal mucosa and colorectal cancer tissues, and study the correlation between ezrin expression in colorectal cancer tissues and tumor invasion and metastasis.
  • METHODS: Eighty paraffin-embedded cancer tissue samples were selected from primary colorectal adenocarcinoma.
  • Forty-five patients and 35 patients had lymph node metastasis.
  • Another 22 paraffin-embedded tissue blocks of normal colorectal epithelium (> 5 cm away from the edge of the tumor) were selected as the control group.
  • All patients with colorectal cancer were treated surgically and diagnosed histologically, without preoperative chemotherapy or radiotherapy.
  • The immunohistochemistry was used to detect the ezrin expression in paraffin-embedded normal colorectal mucosa tissues and colorectal cancer tissue samples.
  • RESULTS: Ezrin expression in colorectal cancer was significantly higher than in normal colorectal mucosa (75.00% vs 9.09%, P < 0.01), and there was a close relationship between ezrin expression and the degree of tumor differentiation, lymph node metastasis and Dukes stage (88.46% vs 50.00%, P < 0.01; 94.28% vs 51.11%, P < 0.01; 94.28% vs 51.11%, P < 0.01).
  • CONCLUSION: Ezrin expression is obviously higher in colorectal cancer tissues than in normal colorectal mucosa tissues, and the high level of ezrin expression is closely related to the colorectal cancer invasion and metastasis process.
  • [MeSH-major] Colorectal Neoplasms. Cytoskeletal Proteins / metabolism. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Female. Humans. Intestinal Mucosa / cytology. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 May 1;61(9):3750-9 [11325848.001]
  • [Cites] Maturitas. 2008 May 20;60(1):31-41 [18486367.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):273-81 [12893187.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):877-83 [14668818.001]
  • [Cites] Microvasc Res. 2004 Jan;67(1):18-28 [14709399.001]
  • [Cites] Gut. 2004 Feb;53(2):235-40 [14724156.001]
  • [Cites] Nat Med. 2004 Feb;10(2):175-81 [14704789.001]
  • [Cites] Nat Med. 2004 Feb;10(2):182-6 [14704791.001]
  • [Cites] Cancer Cell. 2004 Feb;5(2):113-4 [14998486.001]
  • [Cites] Urology. 2004 Mar;63(3):609-12 [15028477.001]
  • [Cites] Trends Mol Med. 2004 May;10(5):201-4 [15121044.001]
  • [Cites] Trends Mol Med. 2004 Jun;10(6):249-50 [15177187.001]
  • [Cites] J Cell Biol. 1994 Jul;126(2):391-401 [7518464.001]
  • [Cites] J Biol Chem. 1996 Mar 22;271(12):7224-9 [8636161.001]
  • [Cites] J Pathol. 1996 May;179(1):74-9 [8691349.001]
  • [Cites] Oncogene. 1996 Sep 19;13(6):1231-7 [8808697.001]
  • [Cites] EMBO J. 1997 Jan 2;16(1):35-43 [9009265.001]
  • [Cites] Trends Biochem Sci. 1996 Dec;21(12):455-8 [9009824.001]
  • [Cites] Curr Biol. 1997 Sep 1;7(9):682-8 [9285722.001]
  • [Cites] J Cell Biol. 1998 Feb 23;140(4):885-95 [9472040.001]
  • [Cites] Biochem Biophys Res Commun. 1999 May 10;258(2):395-400 [10329398.001]
  • [Cites] Breast Cancer Res. 2005;7(3):R365-73 [15987432.001]
  • [Cites] Apoptosis. 2005 Oct;10(5):941-7 [16151629.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3629-38 [16585188.001]
  • [Cites] Infect Immun. 2007 Dec;75(12):5669-77 [17908813.001]
  • [Cites] Cancer Lett. 2008 Mar 8;261(1):55-63 [18155831.001]
  • [Cites] Ai Zheng. 2008 Feb;27(2):165-9 [18279614.001]
  • [Cites] J Cell Sci. 2008 Mar 1;121(Pt 5):644-54 [18270268.001]
  • [Cites] Pediatr Blood Cancer. 2008 Apr;50(4):752-6 [17886294.001]
  • [Cites] Pol J Pathol. 2007;58(4):235-43 [18459457.001]
  • [Cites] Mol Biol Cell. 2003 May;14(5):2181-91 [12802084.001]
  • (PMID = 19399936.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cytoskeletal Proteins; 0 / ezrin
  • [Other-IDs] NLM/ PMC2675094
  •  go-up   go-down


26. Mühlmann G, Spizzo G, Gostner J, Zitt M, Maier H, Moser P, Gastl G, Zitt M, Müller HM, Margreiter R, Ofner D, Fong D: TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol; 2009 Feb;62(2):152-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In gastric cancer the recurrence rate is unacceptably high, even after R0 resection and (neo)adjuvant chemotherapy.
  • Therefore, there is an urgent need for identification of predictive and/or prognostic biomarkers to select high-risk patients who might benefit from additional therapies.
  • Significantly higher expression of TROP2 could be detected in intestinal-type carcinomas (p = 0.03).
  • In intestinal-type gastric cancer, TROP2 overexpression was significantly correlated with shorter disease-free survival (DFS) (p = 0.03).
  • Among the total group, TROP2 overexpression was predictive for poor disease-free (p<0.01) and overall (p = 0.03) survival in lymph node positive patients.
  • Multivariate Cox regression analysis revealed TROP2 overexpression to be an independent prognostic marker for poor DFS in the subgroup of patients with intestinal-type gastric cancer irrespective of lymph node involvement.
  • CONCLUSION: Results show that TROP2 is an independent prognostic marker for disease recurrence in intestinal type gastric cancer.
  • Due to its wide distribution TROP2 may become an attractive therapeutic target in a subgroup of patients with gastric cancer.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / metabolism. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Female. Gastrectomy. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Neoplasm Proteins / metabolism. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18930986.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / W 1101
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / Neoplasm Proteins; 0 / TACSTD2 protein, human
  •  go-up   go-down


27. Mejia A, Schulz S, Hyslop T, Weinberg DS, Waldman SA: Molecular staging estimates occult tumor burden in colorectal cancer. Adv Clin Chem; 2010;52:19-39
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor cells in regional lymph nodes are a key prognostic marker of survival and predictive marker of response to adjuvant chemotherapy in colorectal cancer.
  • However, clinicopathologic techniques to detect lymph node metastases remain imperfect, and approximately 30% of patients with lymph nodes negative by histology (pN0) develop recurrent disease, reflecting occult metastases that escape detection.
  • GUCY2C is a receptor whose expression normally is restricted to intestinal epithelial cells, but is universally overexpressed by colorectal cancer cells.
  • The presence of occult nodal metastases was the most powerful independent predictor of time to recurrence and disease-free survival.
  • These observations establish the utility of molecular detection of occult nodal metastases for assessing prognostic risk in pN0 colorectal cancer patients.
  • Advancing GUCY2C into staging paradigms in clinical laboratories will require validation in independent patient populations, definition of the relationship between the quantity of occult tumor metastases and risk, and determination of the utility of GUCY2C qRT-PCR to identify pN0 patients who might benefit from adjuvant chemotherapy.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Neoplasm Staging / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21275338.001).
  • [ISSN] 0065-2423
  • [Journal-full-title] Advances in clinical chemistry
  • [ISO-abbreviation] Adv Clin Chem
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA112147; United States / NCI NIH HHS / CA / CA75123; United States / NCI NIH HHS / CA / CA95026; United States / NHLBI NIH HHS / HL / K30 HL004522
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Peptide; EC 4.6.1.2 / Guanylate Cyclase; EC 4.6.1.2 / Receptors, Guanylate Cyclase-Coupled; EC 4.6.1.2 / enterotoxin receptor
  •  go-up   go-down


28. Ahmed K, Hoque R, El-Tawil S, Khan MS, George ML: Adenocarcinoma of the appendix presenting as bilateral ureteric obstruction. World J Surg Oncol; 2008;6:23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Adenocarcinoma of the vermiform appendix is a rare neoplasm of the gastrointestinal tract.
  • Presentation mimics acute appendicitis, but right iliac fossa mass and intestinal obstruction have also been reported.
  • Histopathology revealed well differentiated adenocarcinoma with signet ring morphology with multiple lymph node involvement.
  • The patient was referred for chemotherapy where he received infusional 5 fluorouracil but died 7 months after surgery.
  • Every attempt should be made to make a precise diagnosis through all the available means to direct the treatment along correct lines.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Appendiceal Neoplasms / complications. Appendiceal Neoplasms / diagnosis. Ureteral Obstruction / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 2004 Jul;70(7):593-9 [15279181.001]
  • [Cites] Arch Surg. 1977 May;112(5):666-7 [856108.001]
  • [Cites] J La State Med Soc. 1991 Nov;143(11):29-31 [1753179.001]
  • [Cites] Tumori. 1993 Dec 31;79(6):447-9 [8171749.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):154-70 [8000994.001]
  • [Cites] Surg Today. 2005;35(2):168-71 [15674503.001]
  • [Cites] Urology. 2004 May;63(5):981-2 [15135001.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3307-12 [12115365.001]
  • [Cites] Hinyokika Kiyo. 2002 Jun;48(6):351-4 [12166235.001]
  • [Cites] Minerva Chir. 2002 Oct;57(5):597-605 [12370661.001]
  • [Cites] Minerva Chir. 2002 Oct;57(5):695-8 [12370673.001]
  • [Cites] Korean J Gastroenterol. 2004 Jan;43(1):29-34 [14745249.001]
  • [Cites] Eur J Gynaecol Oncol. 2004;25(1):113-5 [15053078.001]
  • [Cites] Rozhl Chir. 2005 Jan;84(1):33-6 [15813454.001]
  • (PMID = 18291037.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2277416
  •  go-up   go-down


29. Fu K, Ishikawa T, Ooyanagi H, Kaji Y, Shimizu H: Multimodality treatments for nodal relapse after endoscopic mucosal resection of a superficial esophageal squamous cell carcinoma. Endoscopy; 2007 Jul;39(7):669-71
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality treatments for nodal relapse after endoscopic mucosal resection of a superficial esophageal squamous cell carcinoma.
  • Patients with esophageal intraepithelial carcinoma (m1) and carcinoma invading the lamina propria (m2) are generally considered good candidates for endoscopic mucosal resection (EMR) in Japan, as hardly any of them show lymph node metastasis.
  • Although a few cases of esophageal carcinoma invading the lamina propria have been reported to show nodal involvement, lymph node metastasis and subsequent death due to carcinoma after EMR of m1 or m2 esophageal carcinoma has never been reported in the English literature.
  • Here we describe a patient who suffered relapse of lymph node metastasis after EMR of an esophageal carcinoma invading the lamina propria without any of the reported risk factors associated with lymph node metastasis, including vascular invasion.
  • Unfortunately, the patient died due to disease recurrence, despite receiving multimodality treatments including chemoradiotherapy and salvage surgery.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / surgery. Endoscopy, Gastrointestinal / methods. Esophageal Neoplasms / surgery. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Aged. Biopsy. Drug Therapy, Combination. Fatal Outcome. Follow-Up Studies. Humans. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Male. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17611925.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


30. Caudry M, Ratoanina JL, Escarmant P, Maire JP: [Target volume in radiotherapy of gastric adenocarcinoma]. Cancer Radiother; 2001 Oct;5(5):523-33
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Les volumes-cibles de la radiothérapie des adénocarcinomes gastriques.
  • A GTV should be considered in preoperative or exclusive radiation therapy.
  • (1) contiguous microscopic extension from deeply invasive T3 and T4 tumors, that remain amenable to local sterilization with doses of 45-50 Gy, delivered in a CTV including the peritoneal cavity at the level of the gastric bed, and under the parietal incision;.
  • (2) true "peritoneal carcinomatosis", with widespread seeds, where chemotherapy (systemic or intraperitoneal) is more appropriate.
  • c) A lymphatic volume including the lymph node groups 1 to 16 of the Japanese classification.
  • In proximal tumors, it is possible to restrict the lower part of the CTV to the lymphatic volume, and therefore to avoid irradiation of large intestinal and renal volumes.
  • In distal and proximal tumors, involvement of resection margins is of poor prognosis--a radiation boost must be delivered at this level.
  • In tumors invading the distal esophagus, a more complete coverage of mediastinal lymph nodes should be considered, especially in patients in good general condition.
  • In contrast, for distal tumors, the hepatic pedicle and the hepatoduodenal ligament should be included whereas the splenic area could be spared.
  • CONCLUSION: Planning the treatment of gastric cancer remains difficult; target volumes must be customized by experienced radiation oncologists according to tumoral and clinical situation.
  • [MeSH-minor] Dose Fractionation. Humans. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm, Residual

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11715304.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 65
  •  go-up   go-down


31. Ingold B, Simon E, Ungethüm U, Kuban RJ, Müller BM, Lupp A, Neumann U, Ebert MP, Denkert C, Weichert W, Schulz S, Röcken C: Vascular CXCR4 expression - a novel antiangiogenic target in gastric cancer? PLoS One; 2010;5(4):e10087
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: G-protein-coupled receptors (GPCRs) are prime candidates for novel cancer prevention and treatment strategies.
  • We searched for differentially expressed GPCRs in node positive gastric carcinomas.
  • METHODOLOGY/PRINCIPAL FINDINGS: Differential expression of GPCRs in three node positive vs. three node negative intestinal type gastric carcinomas was analyzed by gene array technology.
  • The candidate genes CXCL12 and its receptor CXCR4 were validated by real-time reverse-transcription polymerase chain reaction in an independent set of 37 gastric carcinomas.
  • Translation was studied by immunohistochemistry in 347 gastric carcinomas using tissue microarrays as well as in 61 matching lymph node metastases.
  • 52 GPCRs and GPCR-related genes were up- or down-regulated in node positive gastric cancer, including CXCL12.
  • Three lymph node metastases revealed vascular CXCR4 expression while tumour cells completely lacked CXCR4 in all cases.
  • CONCLUSIONS/SIGNIFICANCE: Our results substantiate the significance of GPCRs on the biology of gastric carcinomas and provide evidence that the CXCL12-CXCR4 pathway might be a novel promising antiangiogenic target for the treatment of gastric carcinomas.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Neoplasm Proteins / analysis. Receptors, CXCR4 / analysis. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Angiogenesis Inhibitors / pharmacology. Chemokine CXCL12 / analysis. Chemokine CXCL12 / genetics. Drug Delivery Systems. Female. Gene Expression Profiling. Humans. Male. Microvessels / chemistry. Middle Aged. Receptors, G-Protein-Coupled / analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2005 May;6(5):266 [15889503.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8604-12 [15574767.001]
  • [Cites] FASEB J. 2006 Jan;20(1):59-64 [16394268.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2181-7 [16489019.001]
  • [Cites] Eur J Cancer. 2006 Apr;42(6):768-78 [16510280.001]
  • [Cites] Contrib Microbiol. 2006;13:191-9 [16627966.001]
  • [Cites] J Biol Chem. 2006 Jul 14;281(28):19588-99 [16675446.001]
  • [Cites] Nat Rev Cancer. 2007 Feb;7(2):79-94 [17251915.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1206-12 [17548686.001]
  • [Cites] Cancer Lett. 2007 Oct 28;256(2):137-65 [17629396.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11751-9 [18089805.001]
  • [Cites] Br J Cancer. 2008 May 20;98(10):1682-9 [18443596.001]
  • [Cites] Cancer Lett. 2008 Aug 28;267(2):226-44 [18579287.001]
  • [Cites] PLoS One. 2008;3(12):e4069 [19116653.001]
  • [Cites] Int J Oncol. 2009 Feb;34(2):473-80 [19148483.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):608-11 [19092804.001]
  • [Cites] Histopathology. 2009 Nov;55(5):576-86 [19912363.001]
  • [Cites] Ann Surg Oncol. 2010 Aug;17(8):2051-8 [20177796.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):829-34 [10639165.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1743-50 [15755995.001]
  • [Cites] Curr Pharm Des. 2005;11(9):1167-80 [15853664.001]
  • [Cites] Nucl Med Biol. 2005 Oct;32(7):733-40 [16243649.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):102-11 [10656438.001]
  • [Cites] Immunol Rev. 2000 Oct;177:175-84 [11138774.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Oncogene. 2001 Mar 26;20(13):1556-62 [11313902.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1832-7 [11912162.001]
  • [Cites] FASEB J. 2002 Jul;16(9):1093-5 [12087071.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Sep;3(9):639-50 [12209124.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5930-8 [12384559.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Jun 15;167(12):1676-86 [12626353.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 2:ii31-6 [12810455.001]
  • [Cites] Microcirculation. 2003 Jun;10(3-4):359-70 [12851652.001]
  • [Cites] Nature. 2003 Sep 18;425(6955):307-11 [13679920.001]
  • [Cites] Ann Surg Oncol. 2004 Jun;11(6):629-35 [15150070.001]
  • [Cites] Nature. 1996 Aug 15;382(6592):635-8 [8757135.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9448-53 [9689100.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):981-6 [10233835.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • (PMID = 20386750.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Neoplasm Proteins; 0 / Receptors, CXCR4; 0 / Receptors, G-Protein-Coupled
  • [Other-IDs] NLM/ PMC2851611
  •  go-up   go-down


32. Scherübl H, Klöppel G: [Rectal carcinoids on the rise - update]. Z Gastroenterol; 2009 Apr;47(4):365-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Neuroendokrine Neoplasien des Rektums auf dem Vormarsch - ein Update.
  • Endosonography is the method of choice for determining the size and depth of penetration of the tumours and for detecting lymph node metastases.
  • When invasion of lymph or blood vessels or lymph node metastases are found, surgical resection of the lymph nodes is indicated.
  • Stable somatostatin analogues and interferon-alpha constitute the drug therapies of choice for carcinoid syndrome.
  • As a result of the increasing early detection of rectal carcinoids/carcinomas the prognosis for the patients has improved considerably in the last 30 years.
  • In addition to the early detection of colorectal adenoma and adenocarcinoma, screening colonoscopy also makes possible the early detection and early therapy for neuroendocrine rectal tumours/carcinomas.
  • [MeSH-minor] Colonoscopy. Cross-Sectional Studies. Endosonography. Humans. Incidence. Incidental Findings. Intestinal Mucosa / pathology. Malignant Carcinoid Syndrome / diagnosis. Malignant Carcinoid Syndrome / epidemiology. Malignant Carcinoid Syndrome / pathology. Malignant Carcinoid Syndrome / therapy. Mass Screening. Neoplasm Invasiveness / pathology. Prognosis

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19358064.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 41
  •  go-up   go-down


33. Marx AH, Tharun L, Muth J, Dancau AM, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Brümmendorf TH, Bokemeyer C, Izbicki JR, Sauter G: HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol; 2009 Jun;40(6):769-77
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Her-2 is the molecular target for antibody-based treatment of breast cancer (trastuzumab).
  • The potential benefit of anti-Her-2 therapy is currently investigated in several other HER-2-amplified cancers including gastric cancer.
  • Although HER-2 amplification occurs in more than 10% of gastric cancers, potential heterogeneity of HER-2 amplification and overexpression could represent a major drawback for anti-Her-2 therapy.
  • To address the potential applicability of trastuzumab in gastric cancer, tissue microarray sections of 166 gastric adenocarcinomas and 69 lymph node metastases were analyzed for Her-2 overexpression and amplification using Food and Drug Administration-approved reagents for immunohistochemistry and fluorescence in situ hybridization.
  • Amplification was associated with intestinal tumor phenotype but unrelated to survival, grading, pT, pN, or pM.
  • Identical HER-2 status was found in primary tumor and their matched lymph node metastases.
  • The high level of HER-2 amplification in combination with the homogeneity of its expression in primary and metastatic tumors argues for a possible therapeutic utility of trastuzumab in HER-2-amplified gastric adenocarcinomas.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antigens, Neoplasm / genetics. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / genetics. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Lymphatic Metastasis. Male. Middle Aged. Receptor, ErbB-2 / immunology. Tissue Array Analysis. Trastuzumab

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2011 Jun;42(6):909-10; author reply 910-1 [21571126.001]
  • [CommentIn] Hum Pathol. 2010 Feb;41(2):304-5; author reply 305-6 [19914678.001]
  • (PMID = 19269014.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha; P188ANX8CK / Trastuzumab
  •  go-up   go-down


34. Prakash S, Sarran L, Socci N, DeMatteo RP, Eisenstat J, Greco AM, Maki RG, Wexler LH, LaQuaglia MP, Besmer P, Antonescu CR: Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol; 2005 Apr;27(4):179-87
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors of the intestinal tract that typically occur in adults over the age of 40 years.
  • All five pediatric GISTs occurred in girls, involved the stomach as multiple nodules, showed predominantly an epithelioid morphology, often involved lymph nodes, and lacked KIT or PDGFRA mutations.
  • Although all five patients developed recurrence (four in the liver, three in the peritoneum, and two in both sites), four are still alive with disease.
  • Of the 10 GISTs in young adults, half occurred in the small bowel and had spindle cell morphology, and one case had lymph node metastasis.
  • Seven patients developed recurrence, and at last follow-up two patients had died of disease.
  • GISTs that occur in children are a separate clinicopathologic and molecular subset with predilection for girls, multifocal gastric tumors, and wild-type KIT/PDGFRA genotype.
  • In contrast, GISTs in young adults are a more heterogeneous group, including cases that resemble either the pediatric or the older adult-type tumors.
  • The distinct gene expression profile suggests avenues for investigation of pathogenesis and potential therapeutic strategies.
  • [MeSH-minor] Adolescent. Adult. Amino Acid Sequence. Antineoplastic Agents / therapeutic use. Benzamides. Child. DNA Mutational Analysis. Female. Gene Expression Profiling. Humans. Imatinib Mesylate. Male. Molecular Sequence Data. Neoplasm Recurrence, Local / drug therapy. Oligonucleotide Array Sequence Analysis. Piperazines / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use. Sequence Homology, Amino Acid

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15838387.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA102774; United States / NCI NIH HHS / CA / CA94503; United States / NHLBI NIH HHS / HL / HL/DK55748; United States / NCI NIH HHS / CA / P01 CA 47179-10A1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Number-of-references] 39
  •  go-up   go-down


35. Leitao MM Jr, Barakat RR: Staging and surgical treatment. Cancer Treat Res; 2009;149:35-61
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging and surgical treatment.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Hyperthermia, Induced. Infertility, Female / etiology. Infertility, Female / prevention & control. Intestinal Obstruction / etiology. Intestinal Obstruction / surgery. Lymph Node Excision. Lymphatic Metastasis. Neoadjuvant Therapy. Neoplasm Staging / methods. Palliative Care. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy. Postoperative Complications / etiology. Postoperative Complications / prevention & control. Recurrence. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19763430.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 95
  •  go-up   go-down






Advertisement